LL-37 (Cathelicidin)

Immune & Inflammation
Phase 2

LL-37 is a natural human immune defense molecule (part of the cathelicidin family) that plays a key role in the body's first line of defense against infection. Research explores its antimicrobial, wound healing, and immune-regulating properties.

Last updated March 6, 2026
271 PubMed-Verified Studies
Popular
Research-Driven Dosage Reports
RouteSubcutaneous (SC) · Topical
Dose50–200 mcg
Frequency1× daily
Duration2–4 weeks

Based on published research literature.

Swiss Chems|Exclusive Offer
Coupon
10%
Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Overview of LL-37 (Cathelicidin)

Provides direct antimicrobial activity through membrane disruption while modulating immune responses and promoting wound healing.

Antimicrobial / infection

Disrupts bacterial membranes through electrostatic interactions with phospholipids, and is active against gram-positive, gram-negative bacteria, fungi, and enveloped viruses.

May help prevent and disperse bacterial biofilms (proposed), relevant for chronic infection treatment.

Inflammation / immune

Modulates inflammatory responses by affecting cytokine production, which can enhance or suppress inflammation depending on context.

Attracts monocytes, neutrophils, T cells, and mast cells to infection sites, acting as an alarmin in innate immune response.

May influence TLR signaling pathways (proposed), affecting downstream immune activation.

Tissue repair & recovery

Promotes keratinocyte migration, angiogenesis, and epithelialization, enhancing wound closure.

Affects fibroblasts and endothelial cells (proposed), which may support tissue regeneration

Read Full LL-37 (Cathelicidin) Dosage Guide

Research-backed dosing protocols, timing, and administration details

Browse more in this category

Immune & Inflammation

Related Articles